Delving into the Latest Updates on Toripalimab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-PD1 monoclonal antibody, Terepril monoclonal antibody, Toripalimab-TPZI

+ [15]

Target

PD-1

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersMouth and Tooth Diseases+ [8]

Active Indication

Metastatic Esophageal Squamous Cell CarcinomaNasopharyngeal NeoplasmsOesophageal squamous cell carcinoma recurrent+ [61]

Inactive Indication

Advanced Bile Duct CarcinomaAdvanced Gastric AdenocarcinomaAdvanced Neuroendocrine Neoplasm+ [10]

Originator Organization

Shanghai Junshi Biosciences Co., Ltd.

Active Organization

Shanghai Junshi Biosciences Co., Ltd.

Cancer Hospital Chinese Academy of Medical Sciences

Shanghai Juntuo Biomedical Technology Co Ltd.

+ [4]

Inactive Organization

Antengene Corp. Ltd.

Drug Highest PhaseApproved

First Approval Date

CN (17 Dec 2018),

Melanoma

RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (AU), Priority Review (SG), Conditional marketing approval (CN)

Login to view timeline

Structure/Sequence

Sequence Code 453640391L

Source: *****

Sequence Code 524455911H

Source: *****

This is a non-randomized, open-label, dose-escalation, and dose-expansion Phase Ib/IIa study to evaluate the safety, tolerability, PK profile, and preliminary efficacy of HCB101 in combination therapies in subjects with advanced solid tumors. The trial consists of four cohorts, each including a part I of the dose-escalation phase (Phase Ib) and a part II of the dose-expansion phase (Phase IIa).

Start Date31 Jan 2025

Sponsor / Collaborator

HanchorBio inc

100 Clinical Results associated with Toripalimab

Login to view more data

100 Translational Medicine associated with Toripalimab

Login to view more data

100 Patents (Medical) associated with Toripalimab

Login to view more data

511

Literatures (Medical) associated with Toripalimab

15 Feb 2025·INTERNATIONAL JOURNAL OF CANCER

A new treatment approach of toripalimab in combination with concurrent platinum‐based chemoradiotherapy for locally advanced cervical cancer: A phase II clinical trial

Article

Author: Cao, Yuanjie ; Yuan, Zhiyong ; Li, Junyi ; Chen, Jie ; Shi, Jinming ; Li, Chen

Abstract:

This study investigated the efficacy and safety of toripalimab in combination with concurrent platinum‐based chemoradiation in patients with untreated locally advanced cervical cancer. Eligible patients received toripalimab 240 mg once every 3 weeks in combination with concurrent platinum‐based chemoradiotherapy, followed by the maintenance of toripalimab once every 6 weeks up to 1 year. The primary endpoint was objective response rate (ORR). Secondary endpoints included 2‐year and 3‐year progression‐free survival (PFS) rates, 3‐year overall survival (OS) rate, and safety. Biomarker analysis of PD‐L1 expression and genomic mutational analysis by next‐generation sequencing were conducted, as well as PD‐L1 expression on tumor biopsies. A total of 82 patients were enrolled. The median follow‐up was 21 months (range, 5.2–44.5 months). The ORR and disease control rate were both 87.8% among the 82 patients. Median PFS and OS were not reached. A trend toward longer PFS was observed in the populations with a PD‐L1 combined positive score ≥10, low tumor mutation burden and loss of heterozygosity in human leukocyte antigen (HLA LOH) detected populations. A total of 37 patients experienced treatment‐related adverse events, of which 17 (20.7%) patients experienced grade 3 or higher adverse events. Collectively, toripalimab plus concurrent platinum‐based chemoradiotherapy showed promising antitumor efficacy with acceptable safety profiles in patients with untreated locally advanced cervical cancer.

01 Jan 2025·JTO clinical and research reports

Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study

Article

Author: Lai, Victoria ; Rusch, Valerie W ; Zauderer, Marjorie G ; Adusumilli, Prasad S ; Offin, Michael ; Sauter, Jennifer L ; Ho, Teresa ; Ginsberg, Michelle S ; Wong, Phillip ; Agrawal, Prashasti

Introduction:

WT1 often presents on the surface of diffuse pleural mesotheliomas (DPMs) and is an ideal therapeutic target. Galinpepimut-S (GPS), a tetravalent, non-human leukocyte antigen-restricted, heteroclitic WT1-specific peptide vaccine was safe and effective in early phase clinical trials and upregulates T-cell suppressive programmed death-ligand 1 in the tumor microenvironment of other malignancies. A randomized phase 2 study of adjuvant GPS in patients with DPM trended toward improved median overall survival.

Methods:

To further enhance immunogenicity, we combined GPS with nivolumab, an anti-PD1 monoclonal antibody, in an open-label, single-center phase 1 study, examining tolerability and immunogenicity in patients with previously treated DPM. We enrolled patients with progressive or recurrent DPM treated with at least one course of pemetrexed-based chemotherapy. Patients received two doses of GPS followed by six doses of GPS with intravenous nivolumab every 2 weeks, and up to six additional cycles until disease progression or unacceptable toxicity.

Results:

Ten patients were treated; 70% experienced mostly mild treatment-related adverse events; two experienced a grade 3 or higher adverse event. Three of the 10 patients (30%) reported vaccine-specific T-cell responses. There were no partial responses; three patients had prolonged stable disease with up to 17% decrease in tumor volume. Median progression-free survival was 3.9 months and the median overall survival was 7.4 months.

Conclusions:

Coadministration of GPS and nivolumab reported a tolerable toxicity profile and induced immune responses in a subset of patients, but initial response and survival benefit were limited possibly owing to the small sample size.

01 Jan 2025·JAMA Oncology

Toripalimab for Extensive-Stage Small Cell Lung Cancer

Article

Author: Cali Daylan, Ayse Ece ; Morgensztern, Daniel ; Waqar, Saiama N.

889

News (Medical) associated with Toripalimab

21 Jan 2025

·ir.nanobiotix.com

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (NCT06667908). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. “We believe the true value of JNJ-1900 (NBTXR3) is driven by its potential to address the unmet needs of the millions of patients each year who receive radiotherapy as part of their treatment,” said Laurent Levy, Nanobiotix Chief Executive Officer and Chairman of the Executive Board. “With a clear path to potential registration in head and neck cancer established through NANORAY-312, the first patient dosed in the CONVERGE study in non-small cell lung cancer brings us another step closer to delivering for the large number of patients JNJ-1900 (NBTXR3) is designed to serve.” About NBTXR3 (JNJ-1900) NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas for which the product received a European CE mark in 2019. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors. Radiotherapy-activated NBTXR3 is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors, including in NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study. Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating NBTXR3 across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV, a Johnson & Johnson Company. About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations. Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter Disclaimer This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 24, 2024 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2023 universal registration document filed with the AMF on April 24, 2024, in Nanobiotix’ 2024 semi-annual report under the caption “Supplemental Risk Factor” filed with the SEC on Form 6-K and with AMF on September 18 2024, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC’s website at www.sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly. Contacts Attachment

Phase 2License out/inPhase 3Fast Track

21 Jan 2025

·www.pharmaceutical-technology.com

Junshi partners LEO Pharma for toripalimab distribution in Europe

Junshi has conducted more than 40 company-sponsored clinical studies of the therapy. Credit: PeopleImages.com – Yuri A/Shutterstock. Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to distribute and market the monoclonal antibody, toripalimab, in Europe. The agreement focuses on expanding the accessibility of this cancer treatment to individuals in up to 32 nations. LEO Pharma will manage the distribution, promotion and sales of the antibody across European Union member states, Switzerland, the UK and the European Economic Area. TopAlliance Biosciences Europe will retain its role as the marketing authorisation holder, overseeing product development, manufacturing and other key responsibilities. The collaboration includes financial arrangements such as an upfront payment, milestone payments for potential future indications and a revenue share agreement based on net sales. LEO Pharma thrombosis business unit executive vice-president Jean Monin stated: “We are excited to partner with Junshi Biosciences, supplementing LEO Pharma’s Thrombosis business, which already serves patients with cancer-associated thrombosis. “The distribution and marketing partnership for LOQTORZI brings an important new treatment option to areas of high unmet medical need and focuses on a speciality hospital product that complements our existing heparin-based anti-coagulation treatments for cancer-associated thrombosis and other speciality patients. Leveraging our commercial platform, LOQTORZI will create valuable synergies and drive continued growth.” Developed by Junshi Biosciences, toripalimab targets programmed cell death protein 1 (PD-1), and is used in treating various tumours. Its mechanism involves blocking PD-1 interactions with PD-L1 and PD-L2, enhancing the immune system’s ability to eliminate malignant cells. It has gained marketing approval in more than 35 countries and regions globally. In 2024, the European Commission and the UK Medicines and Healthcare Products Regulatory Agency approved the therapy for two indications, making it the first treatment for nasopharyngeal carcinoma in Europe and a first-line treatment for advanced oesophageal squamous cell carcinoma. Junshi has conducted more than 40 company-sponsored clinical studies of the therapy. In May 2023, Shanghai Junshi Biosciences partnered with Dr. Reddy’s Laboratories to develop and commercialise toripalimab in 21 countries.

Drug ApprovalLicense out/inADCImmunotherapyCSCO

20 Jan 2025

·pipelinereview.com

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

SHANGHAI, China I January 20, 2025 I Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced a distribution and marketing partnership with LEO Pharma for toripalimab in Europe. This collaboration aims to promote the accessibility of toripalimab in Europe, offering high-quality, innovative treatments to patients across up to 32 European countries. Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of multiple malignant tumors. To date, toripalimab has been approved for marketing in over 35 countries and regions around the world. In 2024, toripalimab received approvals from both the European Commission (EC) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the following indications: 1) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC); 2) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). Toripalimab is the first and only drug in Europe for the treatment of NPC, and the only first-line treatment for advanced or metastatic ESCC, regardless of tumor PD-L1 expression status. Under the agreement, LEO Pharma will be responsible for toripalimab’s distribution, promotion, sales, etc., in up to 32 countries, including all member states of the European Union (EU) and the European Economic Area (EEA), as well as Switzerland and the United Kingdom. TopAlliance Biosciences Europe will remain the Marketing Authorization Holder (MAH) for toripalimab in Europe, retaining responsibility for product development, manufacturing, registration, pharmacovigilance, quality management, etc. LEO Pharma will make payments, including an upfront payment, milestone payments if LEO Pharma wishes to pursue any subsequently approved indications, and a revenue share of a double-digit percentage on the net sales of toripalimab throughout the collaboration territory. Dr. Sheng YAO, Senior Vice President of Junshi Biosciences and CEO of TopAlliance Biosciences , said, “The partnership with LEO Pharma has established a significant milestone for Junshi Biosciences in the European market and is closely aligned with the company’s global expansion strategy. Europe has been identified as a pivotal strategic region for the corporate business growth. As the Marketing Authorization Holder (MAH) of the product in Europe, the company has already established a local operational center and is actively collaborating with local health authorities to prepare for the successful commercial launch of toripalimab in Europe. As a century-old multinational pharmaceutical company headquartered in Europe, LEO Pharma has established a mature distribution network and rich marketing expertise in the local markets. By leveraging both parties’ strengths in R&D, manufacturing, and commercialization, we believe toripalimab will be efficiently integrated into the Europe markets benefitting local patients-in-need. Moving forward, we will continue to implement our ‘In China, For Global’ strategy and work with partners to provide high-quality, innovative therapies from China to patients worldwide.” Jean Monin, Executive Vice President of Thrombosis Business Unit, LEO Pharma , commented, “We are excited to partner with Junshi Biosciences, supplementing LEO Pharma’s Thrombosis business, which already serves patients with cancer-associated thrombosis. The distribution and marketing partnership for LOQTORZI® brings an important new treatment option to areas of high unmet medical need and focuses on a specialty hospital product that complement our existing heparin-based anti-coagulation treatments for cancer-associated thrombosis and other specialty patients. Leveraging our commercial platform, LOQTORZI® will create valuable synergies and drive continued growth.” About Toripalimab Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and to induce PD-1 receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells. More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Europe, and Southeast Asia. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin. In the Chinese mainland, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are ten approved indications for toripalimab in the Chinese mainland: The ten indications have been included in the National Reimbursement Drug List (NRDL) (2024 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma, perioperative treatment of NSCLC, treatment of RCC and treatment of TNBC. In October 2024, toripalimab for the treatment of recurrent or metastatic NPC was approved in Hong Kong SAR, China. Internationally, toripalimab has been approved for marketing in the United States, the European Union, India, the UK, Jordan, Australia and other countries and regions. In addition, toripalimab BLAs are under reviews in many countries around the globe, including the Singapore Health Sciences Authority (HSA). About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care through innovation for the benefit of people with skin conditions. LEO Pharma also provides anti-coagulant therapy for cancer patients and other specialty patients. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. LEO Pharma offers a broad portfolio of treatments, serving 100 million patients annually. Headquartered in Denmark, LEO Pharma has a global team of 4,000 people. In 2023, the company generated net sales of $1.6 billion. For more information, please visit: https://www.leo-pharma.com. About Junshi Biosciences Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Five of the company’s products have received approvals in China and international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 35 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI®, and other novel therapies for the prevention and treatment of COVID-19. With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://www.junshipharma.com. SOURCE: Junshi Biosciences

Drug ApprovalLicense out/inAccelerated ApprovalCSCOImmunotherapy

100 Deals associated with Toripalimab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	DB15043

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Metastatic Esophageal Squamous Cell Carcinoma	EU	Tmc Pharma (Eu Ltd.	19 Sep 2024
Metastatic Esophageal Squamous Cell Carcinoma	IS	Tmc Pharma (Eu Ltd.	19 Sep 2024
Metastatic Esophageal Squamous Cell Carcinoma	LI	Tmc Pharma (Eu Ltd.	19 Sep 2024
Metastatic Esophageal Squamous Cell Carcinoma	NO	Tmc Pharma (Eu Ltd.	19 Sep 2024
Nasopharyngeal Neoplasms	EU	Tmc Pharma (Eu Ltd.	19 Sep 2024
Nasopharyngeal Neoplasms	IS	Tmc Pharma (Eu Ltd.	19 Sep 2024
Nasopharyngeal Neoplasms	LI	Tmc Pharma (Eu Ltd.	19 Sep 2024
Nasopharyngeal Neoplasms	NO	Tmc Pharma (Eu Ltd.	19 Sep 2024
Oesophageal squamous cell carcinoma recurrent	EU	Tmc Pharma (Eu Ltd.	19 Sep 2024
Oesophageal squamous cell carcinoma recurrent	IS	Tmc Pharma (Eu Ltd.	19 Sep 2024
Oesophageal squamous cell carcinoma recurrent	LI	Tmc Pharma (Eu Ltd.	19 Sep 2024
Oesophageal squamous cell carcinoma recurrent	NO	Tmc Pharma (Eu Ltd.	19 Sep 2024
Unresectable Esophageal Squamous Cell Carcinoma	EU	Tmc Pharma (Eu Ltd.	19 Sep 2024
Unresectable Esophageal Squamous Cell Carcinoma	IS	Tmc Pharma (Eu Ltd.	19 Sep 2024
Unresectable Esophageal Squamous Cell Carcinoma	LI	Tmc Pharma (Eu Ltd.	19 Sep 2024
Unresectable Esophageal Squamous Cell Carcinoma	NO	Tmc Pharma (Eu Ltd.	19 Sep 2024
Triple Negative Breast Cancer	CN	Shanghai Junshi Biosciences Co., Ltd.	18 Jun 2024
Extensive stage Small Cell Lung Cancer	CN	Shanghai Junshi Biosciences Co., Ltd.	04 Jun 2024
Metastatic Renal Cell Carcinoma	CN	Shanghai Junshi Biosciences Co., Ltd.	02 Apr 2024
Unresectable Renal Cell Carcinoma	CN	Shanghai Junshi Biosciences Co., Ltd.	02 Apr 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic melanoma	NDA/BLA	CN	Shanghai Junshi Biosciences Co., Ltd.	12 Aug 2024
Unresectable Melanoma	NDA/BLA	CN	Shanghai Junshi Biosciences Co., Ltd.	12 Aug 2024
Advanced Hepatocellular Carcinoma	NDA/BLA	CN	Shanghai Junshi Biosciences Co., Ltd.	18 Jul 2024
Nasopharyngeal Cancer, Recurrent	NDA/BLA	EU	Tmc Pharma (Eu Ltd.	14 Nov 2022
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	CN	Shanghai Junshi Biosciences Co., Ltd.	11 Jul 2024
Small cell lung cancer limited stage	Phase 3	US	Shanghai Junshi Biosciences Co., Ltd.	15 Nov 2023
Small cell lung cancer limited stage	Phase 3	CN	Shanghai Junshi Biosciences Co., Ltd.	15 Nov 2023
Small cell lung cancer limited stage	Phase 3	BE	Shanghai Junshi Biosciences Co., Ltd.	15 Nov 2023
Small cell lung cancer limited stage	Phase 3	FR	Shanghai Junshi Biosciences Co., Ltd.	15 Nov 2023
Small cell lung cancer limited stage	Phase 3	GE	Shanghai Junshi Biosciences Co., Ltd.	15 Nov 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR2000039155 (ESMO_IO2024) Manual	Phase 2	thymic carcinoma First line	24	Toripalimab + Paclitaxel + Carboplatin	zwabttwcmz(ykrruqdihx) = ynvpnpingj lbvmrxjiyz (dmqyroymmb, 14.1 - 36.5) View more	Positive	12 Dec 2024
HEPATORCH (PRNewswire) Manual	Phase 3	Hepatocellular Carcinoma	326	特瑞普利单抗+贝伐珠单抗	rvfcbotvob(bavagagrte) = jbozlmpavr lvhnekkelj (tnhzgiybpi ) View more	Positive	29 Sep 2024
				索拉非尼	rvfcbotvob(bavagagrte) = zmeftlmmmt lvhnekkelj (tnhzgiybpi ) View more
NCT03430297 (MELATORCH, PRNewswire) Manual	Phase 3	Melanoma First line	255	特瑞普利单抗	rdaeoxxdgl(hlfemgkcax) = zbnjyeibpf xndwqnwmpj (sgppydkiij ) View more	Positive	29 Sep 2024
				达卡巴嗪	rdaeoxxdgl(hlfemgkcax) = mbcnlcesfu xndwqnwmpj (sgppydkiij ) View more
NCT04005170 (EC-CRT-001, ESMO2024) Manual	Phase 2	Esophageal Squamous Cell Carcinoma	42	Toripalimab plus definitive chemoraditoripalimab	ldajnnfiwm(syqlaqjmoo) = sfxellfcqa rqqqzfdvvz (vnlolmuvhr, 31.9 - 62.8) View more	Positive	16 Sep 2024
				Chemotherapy (paclitaxel and cisplatitoripalimab	-
NCT03926338 (PICC, ESMO2024) Manual	Phase 2	Microsatellite instability-high colorectal cancer Neoadjuvant MSI-High \| Deficient DNA Mismatch Repair (dMMR)	43	Toripalimab 3 mg/kg + Celecoxib 200 mg	ctgmcvmsuo(mvkejfkvpy) = byynyreesr mdokfnxhpn (oszdrpglfw, 70 - 96) Met View more	Positive	16 Sep 2024
				Toripalimab 3 mg/kg	ctgmcvmsuo(mvkejfkvpy) = cwjhhsnlxa mdokfnxhpn (oszdrpglfw, 57 - 88) Met View more
ChiCTR2000030405 (NEOTAX, ESMO2024) Manual	Phase 2	Renal Cell Carcinoma Neoadjuvant	25	Toripalimabaxitinib	bxvccylyfy(zqxgdwuxhp) = bwpsnchgin gcjcnostyh (jfazrddzuu, 62.7 - 97.2) View more	Positive	15 Sep 2024
ChiCTR2000039175 (ESMO2024) Manual	Phase 2	Recurrent Glioblastoma	54	Toripalimab in combination with Anlotinib	zjmqegtekl(gwiagwpulm) = xzijjmfyat ukmczmasja (ymonjkdmif ) View more	Positive	15 Sep 2024
NCT04856631 (ESMO2024) Manual	Phase 1/2	Squamous Cell Carcinoma of Head and Neck First line PD-L1 Positive	43	Toripalimab cetuximab	rzvywitqwl(lnuqsckdcd) = bnsohyunwn ubeupzyfjv (crrgnycauq, 27.0 - 57.9) View more	Positive	14 Sep 2024
NCT06117566 (ESMO2024) Manual	Phase 1/2	Squamous Cell Carcinoma of Head and Neck	65	WX390aToripalimab	vmqkiukvgd(hdnbfwqxgt) = omdszitgii szhkjcokwh (svnbmbnvgp ) View more	Positive	14 Sep 2024
				WX390Toripalimab	tvshxogkew(vlwncelkbr) = ytkmqtaoxh eeibkwmqhv (mpmzumhloe ) View more
ChiCTR2000035573 (ESMO2024) Manual	Phase 2	Non-Small Cell Lung Cancer First line	40	Toripalimab + CIK + Chemotherapy	nlifdpauix(nomhyihhrl) = csetmxzahz orxnfgwlgf (igssqxcxdn ) View more	Positive	14 Sep 2024
				Toripalimab + CIK	nlifdpauix(nomhyihhrl) = dyrhnyvvvd orxnfgwlgf (igssqxcxdn ) View more